Polaris Market Research Releases Multiomics in Drug Discovery Market Outlook 2026-2034: Precision Medicine and AI-Driven Drug Discovery Fuel Market Expansion

New industry analysis projects robust growth in the multiomics in drug discovery market through 2034 as pharmaceutical companies expand investments in precision medicine, AI-powered analytics, and integrated multiomics technologies.

Market Size 2025	Forecast 2034	CAGR 2026-2034	Leading Region
USD 350.05 Million	USD 1,447.23 Million	17.08%	North America

Polaris Market Research & Consulting has released its Multiomics in Drug Discovery Market Report 2026-2034. The market was valued at USD 350.05 million in 2025 and is projected to reach USD 1,447.23 million by 2034, registering a CAGR of 17.08% during the forecast period. The report reveals that market growth is fueled by the rising popularity of precision medicines, increased efforts in pharmaceutical research, and rising application of genomics, proteomics, transcriptomics, and metabolomics technologies in the drug discovery process. Ongoing developments in AI, cloud computing, and bioinformatics tools are also contributing towards the growth of the market.

It has been observed that pharmaceuticals and biotechnology firms are increasingly relying on integrated multiomics strategies to enhance target identification, biomarker discovery, and patient stratification. Rising application of single-cell multiomics, spatial omics, and advanced AI-based analytical tools is helping researchers in gaining insights into the working mechanism of diseases. Strategic alliances between sequencing technology providers and pharmaceutical companies have been instrumental in innovation.

“The use of multiomics technology is revolutionizing drug discovery because it helps gain a better insight into biological mechanisms of diseases and treatment. Using a combination of AI, advanced sequencing, and multiomics analysis allows pharmaceutical organizations to become more productive and help develop precision medicines faster." — Prajakta Bengale, Senior Technology Analyst

Multiomics in Drug Discovery Market Investment Signals 2026

Investment Theme	Market Signal	Business Implication
Precision Medicine Expansion	Increasing adoption of personalized therapeutics	Accelerates multiomics platform demand
AI-Powered Multiomics Analytics	Growing integration of AI in biological research	Improves drug discovery efficiency
Single-cell & Spatial Multiomics	Rising investment in high-resolution molecular profiling	Expands advanced research capabilities
Federated Genomic Data Platforms	Increasing collaborative research initiatives	Supports long-term market growth

Polaris Market Research Analysis

Three Market Developments Reshaping the Multiomics in Drug Discovery Industry in 2026

Precision Medicine Continues to Drive Multiomics Adoption

Pharmaceutical companies are adopting genomics, transcriptomics, proteomics, and metabolomics for better target identification in therapies and development of precision medicines. Increased investment in personalized health care solutions has increased market demand.

AI and Single-cell Technologies Are Accelerating Drug Discovery

Technological developments in AI, single-cell multiomics, spatial omics, and biological foundation models have improved molecular analysis and made it possible for researchers to discover disease mechanisms with high accuracy. Such technological developments have shortened research cycles and improved drug discovery at an early stage.

Strategic Collaborations Are Expanding Multiomics Research

The industry is increasing collaborations to integrate multiomics platforms, increase biological data sets, and enhance bioinformatics capacity. Collaborative research initiatives are accelerating innovation while supporting biomarker-driven drug discovery across pharmaceutical pipelines.

Request a free sample copy or read the full market insights : Multiomics in Drug Discovery Market Report

About the Polaris Multiomics in Drug Discovery Market Report 2026-2034

The report provides a comprehensive analysis of market size, growth opportunities, technology trends, regional outlook, competitive landscape, and investment opportunities across the global multiomics in drug discovery industry. The study supports pharmaceutical companies, biotechnology firms, contract research organizations, sequencing technology providers, investors, research institutions, and healthcare organizations in evaluating market opportunities and competitive positioning.

Report coverage: Market size and CAGR by offering, omics modality, and application | Regional analysis across 5 regions with country-level breakdowns | 12 company profiles with financial benchmarking | Regulatory environment heatmap by country | Technology and innovation landscape | PDF and Excel formats | Customization available by country, region, and segment

Key Companies Profiled

Illumina Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Bruker Corporation
Danaher Corporation
QIAGEN N.V.
Standard BioTools Inc.
Revvity Inc.
Bio-Rad Laboratories Inc.
Pacific Biosciences of California Inc.
Oxford Nanopore Technologies plc
10x Genomics Inc.

Market Segments Covered in the Multiomics in Drug Discovery Market Report

By Offering Outlook (Revenue, USD Million, 2021–2034)

Products
Services
Software and Data

By Omics Modality Outlook (Revenue, USD Million, 2021–2034)

Genomics
Transcriptomics
Proteomics
Metabolomics
Single-cell and Spatial

By Application Outlook (Revenue, USD Million, 2021–2034)

Target Discovery
Biomarker Discovery
Mechanism of Action (MoA) & Drug Repurposing
Patient Stratification

By Regional Outlook (Revenue, USD Million, 2021-2034)

North America

US
Canada

Europe

Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe

Asia Pacific

China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific

Middle East & Africa

Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa

Latin America

Mexico
Brazil
Argentina
Rest of Latin America